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Needs from medical and cosmetic areas have led to the design of novel nanosized
emulsions and solid-in-oil dispersions of proteins. Here, we describe the produc-
tion of those emulsions and dispersions using high-energy methodologies such
as high-pressure homogenization or ultrasound. Recent work has resulted in new
mechanistic insights related to the formation of protein emulsions and disper-
sions. The production method and composition of these formulations can deter-
mine major parameters such as size, stability, and functionality, and therefore
their ﬁnal application. Aqueous nanoemulsions of proteins can be used for drug
delivery, while solid-in-oil dispersions are often used in transdermal applications.
Trends in the Production of Protein Emulsions and Dispersions
Protein formulations based on emulsions and dispersions are one of the most researched areas
in biomedical and pharmaceutical/cosmetic agents. The production technology of such for-
mulations can be found in applications ranging from targeted drug delivery to transdermal
perfusion patches and cosmetics [1–3]. In this context, various methods have been used to
formulate proteins, such as coacervation/desolvation (see Glossary), thermal gelation,
emulsiﬁcation, self-assembly, and solid-in-oil dispersions [4–7].
Nanoemulsions are emulsions with uniform and extremely small droplet size, which have
attracted growing interest as colloidal drug carriers for pharmaceutical applications [8,9].
High-energy emulsiﬁcation methods, such as sonication and high-pressure homogenization,
are widely reported for preparing nanoemulsions [10,11]. The formation and stabilization of the
droplets determines the preparation of a ﬁnely dispersed emulsion [12], where the high-energy
methods are important through the promotion of efﬁcient mass transfer. This phenomenon is
mainly due to the formation of high turbulence that creates molecular agitation. The stabilization
of the newly formed droplets against coalescence is the second step; emulsiﬁers are added to
the system for this purpose [11,13]. The emulsiﬁers can lower the interfacial tension and prevent
the agglomeration and coalescence of the droplets by increasing repulsion forces between
droplets [13–15]. A wide variety of synthetic and natural emulsiﬁers can be used, such as
surfactants, phospholipids, proteins, and polysaccharides [15]. Surfactants play a greater role in
selecting emulsiﬁers due to their amphiphilic molecules, which can be applied in oil/water
interface emulsions, resulting in the dispersion of one phase into another immiscible phase.
Solid-in-oil (S/O) dispersions consist of nanosized protein–surfactant complexes dispersed in an
oil vehicle. S/O dispersions are attractive formulations for improving the dispersibility (or solubili-
zation) of hydrophilic biomolecules such as globular proteins and peptides into the oil phase
[16,17]. The method used to produce S/O dispersion is based on a combined high-energy
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Glossary
Coacervation/desolvation: a
thermodynamically driven self-
assembly process for nanoparticle
preparation, where a desolvating
agent (acetone or ethanol) is added
dropwise continuously to an aqueous
protein solution under continuous
stirring. In some cases, the addition
of crosslinking agents is necessary to
promote the nanoparticle
stabilization.
Emulsiﬁcation: a method widely
used for preparing nanoparticles, in
which an aqueous protein solution is
emulsiﬁed in a nonaqueous medium,
such as oil. There are different
emulsiﬁcation processes, including
high-energy methods, which use
mechanical devices such as high-
pressure homogenizers or ultrasound
generators; and low-energy methods,
which use the stored chemical
energy of the system. For stabilizing
the nanoparticles, chemical or
physical (thermal) crosslinking is
used.
Emulsiﬁer: an agent that helps
emulsions become more stable. The
chemical structures of emulsiﬁers
contain a hydrophilic and
hydrophobic part, and they act by
reducing the interfacial tension
between the oil and water phases.
Globular proteins: the most water-
soluble proteins, which have
polypeptide chains coiled into a
compact shape and a tightly packed
core of hydrophobic amino acids.
Hydrophilic: molecules that tend to
interact with water (either polar or
charged). Hydrophilic side chains
tend to associate with water
molecules or with other hydrophilic
side chains.
Hydrophobic: molecules that tend
to avoid water (nonpolar and
uncharged). Hydrophobic side chains
interact with each other due to their
tendency to minimize their contact
with water or polar side chains.
Nanocarriers: nanoscale drug
delivery systems that transport drugs
or biomolecules; an important
objective is to improve their longevity
in the blood, allowing their
accumulation in pathological areas.
Self-assembly: a nanoparticle
preparation method involving
increasing the hydrophobicity of a
protein; a protein can be made to
self-assemble by breaking disulﬁde
bonds or decreasing primary amine
approach. This method involves the use of equipment, such as high-pressure homogenizer and
ultrasonic probe, which are capable to generate huge amounts of energy for emulsiﬁcation and
dispersion of the protein in an appropriate oil. This technique is an effective alternative method to
formulate poorly water-soluble compounds [18]. S/O dispersion is a type of colloid with a
material in a solid state dispersed in a media in liquid state, and this is generally designated as sol
or suspension [6,18–20]. Nanodispersions are biphasic submicron colloidal dispersion formu-
lations [17].
Here, we focus on the emulsiﬁcation and dispersibility methods that are the most widely used
approaches to obtain stable microscale and/or nanoscale protein formulations (Figure 1) as
promising systems enabling controlled transport and delivery. We review recent works related to
the production of both emulsions and S/O dispersions using high-energy methodologies. These
protein formulations can be used for delivering active components intravenously or in skin
permeation.
The Inﬂuence of Emulsiﬁers in Producing Emulsions and Dispersions
Protein microemulsions and nanoemulsions have been used to stabilize, protect, and deliver
active components in different formulations. Several factors are known to inﬂuence the behavior
of these formulations, including particle size and distribution, emulsiﬁer type and concentration,
aqueous solubility of the dispersed phase, temperature, surface tension, and ionic strength [21].
The nature of the emulsiﬁer is crucial in the formation of an emulsion. The most effective
emulsiﬁers are nonionic or mixtures (e.g., ionic and nonionic, or mixtures of nonionic surfactants).
They can be more effective in emulsiﬁcation for lowering the interfacial tension and stabilizing the
emulsion against ﬂocculation and coalescence. The emulsiﬁer concentration has a direct effect
on emulsion production, especially for obtaining homogeneous and small emulsions.
Protein molecules demonstrate greater mobilities at emulsion interfaces with the microsphere
walls having spherical and regular surfaces, as shown in the schematic illustrations in Figure 2.
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Figure 1. Schematic Illustration of Protein Formulations Based on Emulsiﬁcation and Dispersibility Methods to
obtain Microemulsions and/or Nanoemulsions and Dispersions, under Mechanical High-Energy Methodol-
ogy for Drug Delivery Applications.
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Their penetration into the nonaqueous phase helps to solvate their hydrophobic residues,
which adsorb differently at ﬂuid interfaces [22,23]. The adsorption of globular proteins to oil/
water interfaces promotes clear changes in the conformation of the secondary and tertiary
structures, when compared with the protein in solution. These alterations contribute to greater
stable structures compared with their native structures in solution [10]. Figure 2A shows
microspheres of bovine serum albumin (BSA) produced by high shear forces (i.e., the sonication
method) applied to a biphasic water/hydrophobic solvent system. These high shear forces
induce conformational changes in protein and force the protein to be disposed at the water/
solvent interface, stabilizing the microspheres [24]. Figure 2B shows that the environment in the
inner part of the BSA spheres changes slightly when RNA is loaded within BSA and becomes
more hydrophilic [25].
Sucrose fatty acid esters have been explored as mild nonionic surfactants in the production of
nanodispersion technology, assuming the formation of an external layer of a hydrophobic moiety
(Figure 2C). Sucrose esters comprise mixtures with various degrees of esteriﬁcation. A higher
groups on the protein, or by adding
lipophilic compounds.
Solid-in-oil dispersion: the
dispersion of a nonliquid (i.e., solid-
state) material in a liquid dispersion
media (oil dispersion).
Thermal gelation: a process for
nanoparticle preparation that involves
heat-induced conformational changes
in the protein with unfolding of some
polypeptide segments followed by
protein–protein interactions.
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Figure 2. Schematic Illustration of the Protein Arrangement at the Interface of the Microspheres. (A) Left:
scanning electron microscopy (SEM) image of bovine serum albumin (BSA) microspheres; right: BSA at the interface of an
aqueous/organic phase, showing the hydrophilic residues (red color) interacting with water and the hydrophobic residues
(green color) interacting with the organic phase (adapted from [1,24]). (B) Left: SEM image of RNA-loaded BSA micro-
spheres; right: confocal microscopy images of RNA (red color) encapsulated within BSA (green color). Scale bar = 0.5 mm
(adapted from [1]). (C) Solid-in-oil nanodispersion, using sucrose ester as a surfactant.
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monoester content results in a hydrophilic sucrose ester, whereas a higher esteriﬁcation degree
results in a lipophilic sucrose ester [26]. Their potential in the ﬁelds of pharmaceutical and
cosmetic formulations have been investigated more thoroughly because of their low toxicity
and excellent biodegradability [26,27]. In these ﬁelds of application, sucrose esters with low
hydrophilic–lipophilic balance (HLB) values are particularly valuable because they present
higher hydrophobic character. The HLB varies with the degree of esteriﬁcation of the sucrose
molecule, ranging from 0 to 20, where a lower HLB value indicates a more hydrophobic
molecule.
Formation Mechanisms and Applications of Protein Emulsions
Emulsiﬁcation Methodology Based on Proteins
Proteins are a logical choice as emulsiﬁers/stabilizers of emulsions due to their hydrophilic and
hydrophobic amino acids and high surface activity [28,29]. The adsorption of proteins at oil/
water interfaces of emulsions is an important process in the production of emulsion-based
products in the pharmaceutical industry [28]. Proteins impart emulsion stability by a combination
of steric and electrostatic mechanisms [29]. Upon adsorption, proteins adopt conformations
that are different from their native structures in solution because the adsorption process needs
conformational rearrangement to enable hydrophobic amino acids within the core to interact
with the oil phase [28]. In a study using BSA and n-dodecane as an organic phase, albumin
microspheres were produced. This biphasic system was subjected to high-intensity sonication,
resulting in small and stable microspheres [24]. However, these particles produced by sonication
did not present sizes smaller than 250 nm. Particle size is an important feature for intravenous
therapeutic applications, and nanoparticles smaller than 100 nm can be intravenously adminis-
tered and are taken up by cells more efﬁciently [30].
A recent study describes the production of albumin-based nanoemulsions through the high-
pressure homogenization of a biphasic system [2]. The objective of this study was to develop
stable protein-based nanoemulsions as drug delivery systems for intravenous therapeutic
application. Albumin presents several advantageous characteristics that make it an ideal
candidate for drug delivery, such as its availability, biocompatibility, biodegradability, lack of
toxicity, and lack of immunogenicity [31–33]. In this study, an aqueous phase containing albumin
and a PEGylated surfactant (Poloxamer 407) was emulsiﬁed with vegetable oil, as organic phase,
by high-pressure homogenization (Figure 3A) [2].
Poloxamer 407 is a nonionic surfactant, whose structure is a triblock that contains a central
hydrophobic block of polyoxypropylene (POP) or poly(propylene oxide) (PPO) and two identical
lateral hydrophilic chains of polyoxyethylene (POE) or polyethylene glycol (PEG) [34–36]. This
compound has attracted signiﬁcant pharmacological interest and has been characterized as an
‘inactive’ ingredient for different types of preparations (e.g., intravenous, oral solution, and topical
formulations) [36]. One study introduced Poloxamer 407 in the initial formulation to obtain small
nanoemulsions with the ability to evade the immune system, two important characteristics
required for intravenous administration. The presence of Poloxamer 407 resulted in smaller
albumin-based nanoemulsions (Figure 3A) with improved stealth and decreased macrophage
clearance [2,37]. Because experimentally it is very difﬁcult to clarify the interactions between
Poloxamer 407 and albumin with the oil phase, molecular dynamics simulations were per-
formed. Results demonstrated that the hydrophobic part of Poloxamer 407 (POP block)
interacts preferably with the oil, decreasing hydrophobic interactions between protein and
oil, which can be responsible for reducing the size of nanoemulsions (Figure 3A). PEG chains
interact preferentially with the protein, whereas neutral and hydrophilic surfaces were obtained,
resulting in stealth nanoemulsions [2,37]. These protein-based nanoemulsions present suitable
characteristics that improve their blood circulation time and biodistribution, being good can-
didates for application as drug delivery systems for intravenous application.
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Protein-Based Emulsions as Drug Delivery Systems
Nanoemulsions are used in the pharmaceutical ﬁeld as drug delivery systems for parenteral, oral,
ocular, and dermal administration, being designed to deliver and target drugs by these various
routes of administration [38]. The production of targeted delivery systems has inspired research-
ers to use environmentally friendly coupling methods including tailored liposomes [39], speciﬁc
functionalized nanocapsules [40,41], enzymatic synthesis of conjugates (e.g., antibody–human
serum albumin) [42] and polysaccharide hydrogel systems [43], among others.
The intravenous route, a commonly used route for parenteral administration, allows quick and
complete distribution across the body via the systemic circulation [44]. After intravenous
administration, the drugs in circulation still have to overcome several physical and physiological
barriers to reach their targets [44,45]. Nanocarriers, such as nanoemulsions, with suitable
characteristics for intravenous administration, small size, and desirable surface properties
(Figure 4A), can protect the drugs during systemic circulation, improving their blood circulation
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Figure 3. Mechanism of Production and Intravenous Application of Protein Nanoemulsions. (A) Schematic representation of PEGylated albumin nanoemul-
sion production using the high-pressure homogenization method, highlighting the results obtained by a molecular dynamics simulation of the bovine serum albumin
(BSA)/vegetable oil/Poloxamer 407 system and by size characterization of developed nanoemulsions. The image of the molecular dynamics simulation was created using
visual molecular dynamics (VMD) [79], and rendered with POV-Ray 3.6. (B) Illustration of an application of nanoemulsions functionalized with a targeting agent, folate.
These nanoemulsions as drug delivery systems can be administered intravenously and active targeting for tumor tissues can occur through recognition of the targets
(folate receptor). Abbreviation: PEG, polyethylene glycol.
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time and biodistribution [46]. The functionalization of the nanocarriers with targeting agents
promotes the speciﬁc recognition and binding to the targeted therapeutic sites [47].
Albumin nanoparticles carry reactive groups on their surface (amino, thiol, and carboxylic
groups) that can be used for drug conjugation and/or other surface modiﬁcation [5,48]. There
are several studies that describe the production and functionalization of albumin nanoparticles
through the conjugation of the carboxylic group of the targeting agent, for example, folic acid
(FA), to the amino groups present on the surface of albumin-based nanoparticles [49,50]. Our
group developed functionalized albumin-based nanoemulsions composed of albumin–drug/
targeting agent conjugates [51]. Those functionalized albumin nanoemulsions demonstrated
capacity to release the drugs efﬁciently in vitro, which is a very important characteristic for drug
delivery [51]. These FA-tagged albumin nanoemulsions loaded with a compound that presents
antiproliferative capacity against cancer cells, carbon monoxide releasing molecule-2 (CORM-2),
revealed suitable characteristics for targeted drug delivery in cancer therapy [2,52].
Formation Mechanisms and Applications of Protein S/O Dispersions
S/O Dispersion Technology
S/O dispersion has been developed as a novel oil-based dispersion for innovative drug delivery
systems. The method of S/O dispersion was originally established in 1997 as a tool for enzymatic
catalysis in organic media, and various studies were carried out using S/O nanodispersions [53]. The
process in which water-in-oil (W/O) emulsion is lyophilized has many advantages in creating S/O
dispersion containing proteins. The complex surfactant–protein is easily dispersed into the oil until a
homogeneous and transparent oil-based protein dispersion is obtained, without loss of yield. Before
this procedure was proposed, the penetration yield of proteins was very low (under 30%), except for
(A) PEGylated Nanoemulsion
Protein Oil
++
Poloxamer 407
Blood vessel
Nanodispersion
Applicaon of nanodispersion in
a skin model
Diﬀusion to the epidermis
Diﬀusion to the dermis
Diﬀusion to the stratum corneum
Oil
Surfactant/protein
complex
Surfactant Protein
Stratum corneum
Epidermis
Dermis
Dubcutaneous
ssue
+ +
Z-
av
er
ag
e 
(d
.n
m
) 250
200
150
100
50
0
0 1 2 3 4 5 6
[Poloxamer 407] (mg/mL)
(B)
Figure 4. Applications of Nanoemulsions and Solid-in-Oil Nanodispersions. Illustration of (A) intravenous ther-
apeutic applications and (B) transdermal perfusion, showing that the size and surface of emulsions and solid-in-oil (S/O)
dispersions are crucial properties to achieve successful applications.
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lipophilic proteins such as lipase [6]. The delivery of globular proteins is difﬁcult because of their
hydrophilic nature and their high molecular weight. This poor penetration into the skin is mainly due to
the hydrophobic character of the stratum corneum (SC), the outermost layer of the skin [54]. S/O
dispersion allows protein penetration through the intrinsic barrier of the skin assisted by surfactants
and an oil vehicle (Figure 4B). In vitro permeation proﬁles through pig skin were investigated and
conﬁrmed the penetration of nanodispersions. The permeation results were represented with
confocal laser microscopy by 3D imaging (Figure 4B). This 3D image represents the reconstruction
of z-stack confocal images. Reconstructions were made using ‘Imaris’ image analysis software.
S/O methodology to incorporate a large protein of 66 kDa (BSA) was based on the methods of
Tahara et al. and was further optimized [3,55]. This method consists of a complex between
sucrose ester surfactant and the protein formed by high-pressure homogenization as a ﬁrst step.
Then, a lyophilization step is necessary to eliminate the solvent used for surfactant solubilization,
attaining a solid surfactant–protein complex. This complex is then dispersed in an appropriate
oil, such as isopropyl myristate (IPM), by ultrasonication (ultrasound probe, 20 KHz) (Figure 5A).
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Figure 5. Mechanism of Production and Transdermal Application of Solid-in-Oil Nanodispersions. (A) Sche-
matic representation of solid-in-oil (S/O) nanodispersion production, which comprises three stages: (i) addition of sucrose
ester (surfactant) to bovine serum albumin (BSA) solution to form a surfactant–protein complex by high-pressure homo-
genization; (ii) lyophilization of the complex to remove water and chloroform; and (iii) dispersion of the solid complex in oil
(isopropyl myristate) by ultrasonication to form the ﬁnal S/O nanodispersion. (B) Illustration of transdermal perfusion
application of the S/O nanodispersions.
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In the S/O protein nanodispersions, complexes are formed by coating the protein with hydropho-
bic surfactants. Sucrose esters, which are nonionic with low HLB, determined their dispersion
within the oil phase. The oil used in the dispersion phase, IPM, enhanced the skin penetration
properties and increased the diffusion of the nanodispersion in the SC and/or the partition
coefﬁcient between the SC and the oil vehicle [56]. This oil acts upon the SC by liquefying the
lamellar gel phase of the SC lipids and eventually partially dissolving them [57]. IPM is also able to
dissolve considerable amounts of cholesterol, which may act as a membrane stabilizer [58]. The
molecular dynamics simulations results, using the GROMACS [59] package and using the
coarse grained force ﬁeld MARTINI [60], revealed the signiﬁcant importance of each component
in the formulation. IPM strongly inﬂuences the interaction between the dispersion and lipids, while
the surfactant molecules solubilize the hydrophilic protein within the oil [3]. With regard to stability,
S/O nanodispersion showed good storage stability over approximately 2 months.
Protein-Based S/O Dispersions as Transdermal Delivery Systems
Proteins have created huge challenges to creating formulations for transdermal delivery systems
due to their unfriendly physicochemical properties. The design of an approach to protect the
protein from enzymatic degradation enhancing its delivery without altering its biological activity
has been the basis of several studies. Many attempts have been made to formulate an
appropriate delivery system for proteins, with major emphasis on noninvasive routes such
as transdermal patches [61]. Researchers have developed formulations including solid lipid
nanoparticles, biodegradable polymers, chitosan nanoparticles, microspheres, liposomes,
hydrogels, microemulsions, and/or nanoemulsions, among others, for protein delivery [62–68].
The transdermal delivery system represents an attractive alternative to other administration
routes, especially oral and intravenous, which are the most common routes. The most important
advantages of the transdermal transport system are noninvasiveness, prolonged delivery with
the transdermal drug delivery system, avoidance of liver or gastrointestinal metabolism, and
good acceptance by patients [69]. Over the past few decades, there has been a concerted effort
to develop new and practical methods to enhance transdermal delivery, since several lipids can
be found in the SC of human skin, the most important being ceramides, free fatty acids,
cholesterol, and cholesterol sulfate. The vast majority of transdermal drug formulations are
based on the passive diffusion of compounds with low molecular weights and on lipophilic drugs
that permeate the skin.
However, for many hydrophilic molecules with a molecular weight greater than 500 Da [61], skin
penetration is generally poor. The most therapeutic and pharmaceutical valuable proteins are
typically greater than 500 Da, which greatly decreases their skin penetration [70–72]. It has been
reported that larger proteins of 27 and 40 kDa gave limited perfusion results [16,55,72,73].
Another study demonstrated successful transdermal delivery of large proteins for skin vaccina-
tion using an external photodermal effect [74]. The S/O nanodispersion formulation produced by
Martins et al. demonstrated successful skin penetration of a large protein (66 kDa) for a range of
medical and pharma/cosmetic applications (Figure 5B) [3]. Another study demonstrated a
nanodispersion of hyaluronic acid (HA) conjugated with BSA that successfully penetrated
the skin layers into the dermis [75]. The S/O nanodispersion technique has also been developed
to achieve transdermal immunization responses through the effective transcutaneous delivery of
other hydrophilic molecules such as some antigens [76–78].
Concluding Remarks
The functionality of emulsions and S/O dispersions of proteins greatly depends on the formula-
tion used. The addition of a PEGylated surfactant, Poloxamer 407, induced the production of
nanoemulsions with suitable characteristics for intravenous therapeutic applications: small size
(around 100 nm) and stealth behavior (PEGylated surface) (Figure 4A). The design of S/O
Outstanding Questions
Will emulsiﬁcation and dispersibility
methodologies be able to produce a
desirable formulation for drug delivery
and transdermal applications?
Is the use of high-energy approaches
necessary for the production of protein
emulsions and dispersions?
How will the delivery of active compo-
nents intravenously or by skin perme-
ation beneﬁt with better understanding
of protein formulations based on emul-
sions and dispersions?
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nanodispersions, however, assumes the formation of an external layer of a hydrophobic moiety
that can cover the hydrophilic surface of the protein. The resultant S/O dispersion, with sizes
around 150 nm, allows the perfusion of large hydrophilic molecules through the SC barrier of the
skin (Figure 4B); this method can overcome the challenge of the 500 Da rule for skin permeation
of hydrophilic molecules.
Strategies for the design of novel emulsions and S/O dispersions will depend on the speciﬁc
needs of the required applications. The delivery of active components intravenously or by skin
permeation will beneﬁt greatly from the platform discussed in this review (see Outstanding
Questions). Future strategies to produce novel emulsions and dispersions for hydrophilic active
components are expected to have broader ﬁnal target applications. We hope that drug delivery
applications can beneﬁt from continued advances in emulsions and dispersions under mechani-
cal high-energy methodologies.
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